# A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms

> **NCT05212532** · PHASE1 · UNKNOWN · sponsor: **EOM Pharmaceuticals** · enrollment: 40 (estimated)

## Conditions studied

- COVID-19 Pneumonia
- COVID-19 Respiratory Infection
- COVID-19 Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** EOM613

## Key facts

- **NCT ID:** NCT05212532
- **Lead sponsor:** EOM Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-09
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-03-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05212532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05212532, "A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05212532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*